Calcium release channel on the sarcoplasmic reticulum of cardiomyocytes (ryanodine receptor type 2, RyR2) plays a critical role in the regulation of calcium and was identified as a crucial factor for development of chronic anthracycline cardiomyopathy. Its early stages are less well described although these determine the later development. Hence, we tested the effect of repeated, short-term anthracycline (daunorubicin) administration on cardiac performance, cardiomyocyte function and accompanied changes in calcium regulating proteins expression. Ten-twelve weeks old male Wistar rats were administered with 6 doses of daunorubicin (DAU, 3 mg/kg, i.p., every 48 h), controls (CON) received vehicle. Left ventricular function (left ventricular pressure, LVP; rate of pressure development, +dP/dt and decline, -dP/dt) was measured using left ventricular catheterization under tribromethanol anaesthesia (15 ml/kg b.w.). Cell shortening was measured in enzymatically isolated cardiomyocytes. The expressions of RyR2 and associated intracellular calcium regulating proteins, cytoskeletal proteins (alpha-actinin, alpha-tubul in) as well as oxidative stress regulating enzymes (gp91phox, MnSOD) were detected in ventricular tissue samples using immunoblotting. mRNA expressions of cardiac damage markers (Nppa and Nppb, atrial and brain natriuretic peptides; Myh6, Myh7 and Myh7b, myosin heavy chain alpha and beta) were detected using RT-PCR. Thiobarbituric acid reactive substances concentration was measured to estimate oxidative stress. DAU rats exhibited significantly depressed left ventricular features (LVP by 14%, +dP/dt by 36% and -dP/dt by 30%; for all P<0.05), in line with concomitant increase in Nppa and Nppb gene expressions (3.23- and 2.18-fold, for both P<0.05), and a 4.34-fold increase in Myh7 (P<0.05). Controversially, we observed increased cell shortening of isolated cardiac cells by 31% (p<0.05). DAU administration was associated with a twofold upregulation of RyR2 (P<0.05), but not of other examined Ca(2+) regulating proteins remained. In addition, we observed a significant reduction in alpha-tubulin (by 46% when compared to CON P<0.05). Indicators of oxidative injury were unaffected. In conclusion, unbalanced RyR2 overexpression plays a particular role in early development of daunorubicin cardiomyopathy characterized by discrepant in situ versus in vitro cardiac performance.

Department of Pharmacology and Toxicology Faculty of Pharmacy Comenius University Bratislava Slovak Republic

Department of Pharmacology and Toxicology Faculty of Pharmacy Comenius University Bratislava Slovak Republic ; Institut für Pharmakologie und Toxikologie Universitätsklinikum Münster Münster Germany

Institut für Pharmakologie und Toxikologie Universitätsklinikum Münster Münster Germany

Institute of Experimental Pharmacology Slovak Academy of Sciences Bratislava Slovak Republic

International Clinical Research Center St Anne's University Hospital and Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol. 2007;7:114–121. PubMed

Roziakova L, Mistrik M, Batorova A, Kruzliak P, Bojtarova E, Dubrava J, Gergel J, Mladosievicova B. Can We Predict Clinical Cardiotoxicity with Cardiac Biomarkers in Patients After Haematopoietic Stem Cell Transplantation? Cardiovasc Toxicol. 2015;15:210–6. PubMed

Georgakopoulos P, Roussou P, Matsakas E, Karavidas A, Anagnostopoulos N, Marinakis T, Galanopoulos A, Georgiakodis F, Zimeras S, Kyriakidis M, Ahimastos A. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol. 2010;85:894–896. PubMed

Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC 2nd, Shaikh SL, Mone SM, Gelber RD, Colan SD. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J. Clin. Oncol. 2002;20:4517–4522. PubMed

Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol. 2007;23:15–25. PubMed

van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011:CD003917. PubMed

Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009;61:154–171. PubMed

Egom EE, Kruzliak P, Rotrekl V, Lei M. The effect of the sphingosine-1-phosphate analogue FTY720 on atrioventricular nodal tissue. J Cell Mol Med. 2015;19:1729–1734. doi: 10.1111/jcmm.12549. PubMed PMC

Wagner R, Piler P, Gabbasov Z, Maruyama J, Maruyama K, Nicovsky J, Kruzliak P. Adjuvant cardioprotection in cardiac surgery: update. Biomed Res Int. 2014;2014:808096. doi: 10.1155/2014/808096. PubMed PMC

Braunwald E. Heart failure. JACC Heart Fail. 2013;1:1–20. PubMed

Hanna AD, Janczura M, Cho E, Dulhunty AF, Beard NA. Multiple actions of the anthracycline daunorubicin on cardiac ryanodine receptors. Mol Pharmacol. 2011;80:538–549. PubMed

Hanna AD, Lam A, Tham S, Dulhunty AF, Beard NA. Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A. Mol Pharmacol. 2014;86:438–449. PubMed PMC

Boucek RJ Jr, Dodd DA, Atkinson JB, Oquist N, Olson RD. Contractile failure in chronic doxorubicin-induced cardiomyopathy. J Mol Cell Cardiol. 1997;29:2631–2640. PubMed

Boucek RJ Jr, Miracle A, Anderson M, Engelman R, Atkinson J, Dodd DA. Persistent effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol. 1999;31:1435–1446. PubMed

Kim SY, Kim SJ, Kim BJ, Rah SY, Chung SM, Im MJ, Kim UH. Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes. Exp Mol Med. 2006;38:535–545. PubMed

Soga M, Kamal FA, Watanabe K, Ma M, Palaniyandi S, Prakash P, Veeraveedu P, Mito S, Kunisaki M, Tachikawa H, Kodama M, Aizawa Y. Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. Int J Cardiol. 2006;110:378–385. PubMed

Matsushita T, Okamato M, Toyama J, Kodama I, Ito S, Fukutomi T, Suzuki S, Itoh M. Adriamycin causes dual inotropic effects through complex modulation of myocardial Ca2+ handling. Jpn Circ J. 2000;64:65–71. PubMed

Cernecka H, Ochodnicka-Mackovicova K, Kucerova D, Kmecova J, Nemcekova V, Doka G, Kyselovic J, Krenek P, Ochodnicky P, Klimas J. Enalaprilat increases PPARbeta/delta expression, without influence on PPARalpha and PPARgamma, and modulate cardiac function in sub-acute model of daunorubicin-induced cardiomyopathy. Eur J Pharmacol. 2013;714:472–477. PubMed

Kelso EJ, Geraghty RF, McDermott BJ, Cameron CH, Nicholls DP, Silke B. Characterisation of a cellular model of cardiomyopathy, in the rabbit, produced by chronic administration of the anthracycline, epirubicin. J Mol Cell Cardiol. 1997;29:3385–3397. PubMed

Timolati F, Ott D, Pentassuglia L, Giraud MN, Perriard JC, Suter TM, Zuppinger C. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol. 2006;41:845–854. PubMed

Gyorke S, Terentyev D. Modulation of ryanodine receptor by luminal calcium and accessory proteins in health and cardiac disease. Cardiovasc Res. 2008;77:245–255. PubMed

Kučerová D, Baba HA, Bokník P, Fabritz L, Heinick A, Mát’uš M, Müller FU, Neumann J, Schmitz W, Kirchhefer U. Modulation of SR Ca2+ release by the triadin-to-calsequestrin ratio in ventricular myocytes. Am J Physiol Heart Circ Physiol. 2012;302:H2008–2017. PubMed

Bers DM. Macromolecular complexes regulating cardiac ryanodine receptor function. J Mol Cell Cardiol. 2004;37:417–429. PubMed

Yano M, Ono K, Ohkusa T, Suetsugu M, Kohno M, Hisaoka T, Kobayashi S, Hisamatsu Y, Yamamoto T, Kohno M, Noguchi N, Takasawa S, Okamoto H, Matsuzaki M. Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca(2+) leak through ryanodine receptor in heart failure. Circulation. 2000;102:2131–2136. PubMed

Matus M, Kucerova D, Kruzliak P, Adameova A, Doka G, Turcekova K, Kmecova J, Kyselovic J, Krenek P, Kirchhefer U, Mueller FU, Boknik P, Klimas J. Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat. Mol Cell Biochem. 2015;403:199–208. PubMed

Arai M, Tomaru K, Takizawa T, Sekiguchi K, Yokoyama T, Suzuki T, Nagai R. Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J Mol Cell Cardiol. 1998;30:243–254. PubMed

Burke BE, Gambliel H, Olson RD, Bauer FK, Cusack BJ. Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the rat. Br J Pharmacol. 2000;131:1–4. PubMed PMC

Kmecova J, Klimas J. Heart rate correction of the QT duration in rats. Eur J Pharmacol. 2010;641:187–192. PubMed

Klimas J, Kmecova J, Jankyova S, Yaghi D, Priesolova E, Kyselova Z, Musil P, Ochodnicky P, Krenek P, Kyselovic J, Matyas S. Pycnogenol improves left ventricular function in streptozotocin-induced diabetic cardiomyopathy in rats. Phytother Res. 2010;24:969–974. PubMed

Olson RD, Gambliel HA, Vestal RE, Shadle SE, Charlier HA Jr, Cusack BJ. Doxorubicin cardiac dysfunction: effects on calcium regulatory proteins, sarcoplasmic reticulum, and triiodothyronine. Cardiovasc Toxicol. 2005;5:269–283. PubMed

Charlier HA Jr, Olson RD, Thornock CM, Mercer WK, Olson DR, Broyles TS, Muhlestein DJ, Larson CL, Cusack BJ, Shadle SE. Investigations of calsequestrin as a target for anthracyclines: comparison of functional effects of daunorubicin, daunorubicinol, and trifluoperazine. Mol Pharmacol. 2005;67:1505–1512. PubMed

Zucchi R, Yu G, Ghelardoni S, Ronca F, Ronca-Testoni S. Effect of MEN 10755, a new disaccharide analogue of doxorubicin, on sarcoplasmic reticulum Ca(2+) handling and contractile function in rat heart. Br J Pharmacol. 2000;131:342–348. PubMed PMC

Wehrens XH, Lehnart SE, Huang F, Vest JA, Reiken SR, Mohler PJ, Sun J, Guatimosim S, Song LS, Rosemblit N, D’Armiento JM, Napolitano C, Memmi M, Priori SG, Lederer WJ, Marks AR. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell. 2003;113:829–840. PubMed

Cai C, Lothstein L, Morrison RR, Hofmann PA. Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198) J Pharmacol Exp Ther. 2010;335:223–230. PubMed PMC

de Beer EL, Bottone AE, van Rijk MC, van der Velden J, Voest EE. Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics. Br J Pharmacol. 2002;135:1707–1714. PubMed PMC

Pazos-Moura C, Abel ED, Boers ME, Moura E, Hampton TG, Wang J, Morgan JP, Wondisford FE. Cardiac dysfunction caused by myocardium-specific expression of a mutant thyroid hormone receptor. Circ Res. 2000;86:700–706. PubMed

Wiesner RJ, Ehmke H, Faulhaber J, Zak R, Ruegg JC. Dissociation of left ventricular hypertrophy, beta-myosin heavy chain gene expression, and myosin isoform switch in rats after ascending aortic stenosis. Circulation. 1997;95:1253–1259. PubMed

Holubarsch C, Goulette RP, Litten RZ, Martin BJ, Mulieri LA, Alpert NR. The economy of isometric force development, myosin isoenzyme pattern and myofibrillar ATPase activity in normal and hypothyroid rat myocardium. Circ Res. 1985;56:78–86. PubMed

Gupta MP. Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure. J Mol Cell Cardiol. 2007;43:388–403. PubMed PMC

Krenz M, Robbins J. Impact of beta-myosin heavy chain expression on cardiac function during stress. J Am Coll Cardiol. 2004;44:2390–2397. PubMed

Kostin S, Hein S, Arnon E, Scholz D, Schaper J. The cytoskeleton and related proteins in the human failing heart. Heart Fail Rev. 2000;5:271–280. PubMed

Saks V, Kuznetsov AV, Gonzalez-Granillo M, Tepp K, Timohhina N, Karu-Varikmaa M, Kaambre T, Dos Santos P, Boucher F, Guzun R. Intracellular Energetic Units regulate metabolism in cardiac cells. J Mol Cell Cardiol. 2012;52:419–436. PubMed

Zhang C, Chen B, Guo A, Zhu Y, Miller JD, Gao S, Yuan C, Kutschke W, Zimmerman K, Weiss RM, Wehrens XH, Hong J, Johnson FL, Santana LF, Anderson ME, Song LS. Microtubule-mediated defects in junctophilin-2 trafficking contribute to myocyte transverse-tubule remodeling and Ca2+ handling dysfunction in heart failure. Circulation. 2014;129:1742–1750. PubMed PMC

Tsutsui H, Tagawa H, Kent RL, McCollam PL, Ishihara K, Nagatsu M, Cooper G 4th. Role of microtubules in contractile dysfunction of hypertrophied cardiocytes. Circulation. 1994;90:533–555. PubMed

Hein S, Kostin S, Heling A, Maeno Y, Schaper J. The role of the cytoskeleton in heart failure. Cardiovasc Res. 2000;45:273–278. PubMed

van Hoorn F, Campian ME, Spijkerboer A, Blom MT, Planken RN, van Rossum AC, de Bakker JM, Wilde AA, Groenink M, Tan HL. SCN5A mutations in Brugada syndrome are associated with increased cardiac dimensions and reduced contractility. PLoS One. 2012;7:e42037. PubMed PMC

Xiong Q, Cao Q, Zhou Q, Xie J, Shen Y, Wan R, Yu J, Yan S, Marian AJ, Hong K. Arrhythmogenic cardiomyopathy in a patient with a rare loss-of-function KCNQ1 mutation. J Am Heart Assoc. 2015;4:e001526. PubMed PMC

Arozal W, Watanabe K, Veeraveedu PT, Ma M, Thandavarayan RA, Sukumaran V, Suzuki K, Kodama M, Aizawa Y. Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology. 2010;274:18–26. PubMed

Dhingra R, Margulets V, Chowdhury SR, Thliveris J, Jassal D, Fernyhough P, Dorn GW 2nd, Kirshenbaum LA. Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling. Proc Natl Acad Sci U S A. 2014;111:E5537–5544. PubMed PMC

Hydock DS, Lien CY, Hayward R. Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model. J Cardiovasc Pharmacol Ther. 2009;14:59–67. PubMed

Fogli S, Nieri P, Breschi MC. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004;18:664–675. PubMed

Jackson JA, Reeves JP, Muntz KH, Kruk D, Prough RA, Willerson JT, Buja LM. Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity. Am J Pathol. 1984;117:140–153. PubMed PMC

Polanski AK, Ebner A, Ebner B, Hofmann A, Steinbronn N, Brandt A, Forkmann M, Tausche AK, Morawietz H, Strasser RH, Wunderlich C. Dexrazoxane prevents the development of the impaired cardiac phenotype in caveolin-1-disrupted mice. J Cardiovasc Pharmacol. 2013;61:545–552. PubMed

Lipshultz SE, Sambatakos P, Maguire M, Karnik R, Ross SW, Franco VI, Miller TL. Cardiotoxicity and cardioprotection in childhood cancer. Acta Haematol. 2014;132:391–399. PubMed

Hrdina R, Gersl V, Klimtova I, Simunek T, Machackova J, Adamcova M. Anthracycline-induced cardiotoxicity. Acta Medica (Hradec Kralove) 2000;43:75–82. PubMed

Downregulation of myogenic microRNAs in sub-chronic but not in sub-acute model of daunorubicin-induced cardiomyopathy